-
Multiples Alternate Asset Management led consortium to acquire Zydus Cadila’s animal health business
expresspharma
May 13, 2021
The consortium including Multiples, Canada Pension Plan Investment Board and RARE Enterprises will buy Zydus AH in a $400 million deal.
-
'Dr. Google' Helps Some Patients Diagnose a Rare Disease
drugs
August 20, 2019
A middle-aged woman had persistent symptoms that doctors couldn't explain. Frustrated, she took an increasingly common route: a search through the internet.
-
For Kids With Rare Condition, 'Restricted' Diets Can Turn Dangerous
drugs
July 12, 2019
For Kids With Rare Condition, 'Restricted' Diets Can Turn Dangerous.
-
FDA approves treatment for rare neurological disorder
europeanpharmaceuticalreview
July 05, 2019
An injection to treat NMOSD has been given approval by the FDA and has received orphan drug designation.
-
AHA News: Study Provides Rare Look at Stroke Risk, Survival Among American Indians
drugs
June 14, 2019
Study Provides Rare Look at Stroke Risk, Survival Among American Indians.
-
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease
pharmatimes
May 09, 2019
Pfizer's Vyndaqel, Vyndamax win US nod for rare disease.
-
FDA Approves Treatments for Heart Failure Caused by Rare Disease
drugs
May 07, 2019
FDA Approves Treatments for Heart Failure Caused by Rare Disease.
-
PI3K inhibitors show hope for rare bone cancers
europeanpharmaceuticalreview
May 06, 2019
Scientists have used genome sequencing to gain a better understanding of the biology underlying chordoma…
-
Rare melanoma type highly responsive to immunotherapy
europeanpharmaceuticalreview
April 30, 2019
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
-
Sanofi concludes option phase of rare disease alliance with Alnylam
pharmaceutical-technology
April 23, 2019
Sanofi concludes option phase of rare disease alliance with Alnylam.